The jab averse can now rejoice! Drug manufacturer Eli Lilly announced this week that an encouraging clinical trial of their new pill promises a convenient, stab-free way to treat diabetes and obesity.

“The secret story behind the birth of ‘Saiyaman X‘ that I got to draw for the end of this volume was based on text written by Toriyama-sensei, which I revised and made into a manga ...

Dragon Ball Super’s very own Toyotaro just hit fans right in the feels with a powerful tribute to the late, great Akira Toriyama. Captioned with the simple but soul-punching line “Toriyama’s ...

Jonathan Bell has written for Wallpaper* magazine since 1999, covering everything from architecture and transport design to books, tech and graphic design. He is now the magazine’s Transport and ...

UNITED STATES – Pfizer is ending the development of its potential once-daily pill treatment for obesity after venturing into the biggest and most expensive level of clinical testing. The ...

A new study finds that access to abortion services expanded greatly in the five years after the abortion pill was approved and pharmacies began dispensing it in Ontario, but that surgical ...

The winner is announced on 9 December 2025 Hannah Silver is the Art, Culture, Watches & Jewellery Editor of Wallpaper*. Since joining in 2019, she has overseen offbeat design trends and in-depth ...

"The red pill is like, 'I see the truth.' It’s a call to action by the manosphere,” Adam, played by Amari Bacchus, says in the show about an Instagram comment. “She’s saying he’s an incel.” What does ...

Dubbed the "Biden Pill Penalty" by critics, the measure has reportedly led to a 70 percent drop in investment in small-molecule drug development since 2021. Under the policy, these more accessible ...

The Trump administration's decision to exempt tariffs on Indian pharma imports brings relief to a $9 billion-plus US export market, highlighting India's key role in providing affordable generic ...

The so-called "pill penalty" — a flaw in the act's drug pricing provisions — disproportionately harms small-molecule drugs, which account for more than 90% of prescriptions in the United States.

It positions the pharma to dominate the oral GLP-1 market. The pill achieved 7.9% weight loss (16 pounds) and 1.3% to 1.6% A1C reduction in diabetes patients over 40 weeks, rivaling Novo Nordisk ...